
Insider and congress filings
Becton, Dickinson and Company (BDX)
NYSE · Healthcare · 371 insider transactions · 133 congress trades · last filed 26 days agoS&P 500
About Becton, Dickinson and Company
from the company's filings and listing, as of Oct 24, 2026- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Chief executive
- Thomas E. Polen Jr.
- Employees
- 72,000
- Listed since
- -
- Market value
- $54.2B
- Price to earnings (12 mo)
- 59.9
- Net income per share, as reported (12 mo)
- $3.42
- Dividend yield
- 2.00%
Earnings
6 reported quarters · next on Nov 5, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q3 FY2026reported Aug 6, 2026 | $3.23 | $3.14 | $5.0B | $4.9B | EPS beatRevenue beat |
| Q2 FY2026reported May 7, 2026 | $2.90 | $2.78 | $4.7B | $4.7B | EPS beatRevenue in line |
| Q1 FY2026reported Feb 9, 2026 | $2.91 | $2.21 | $4.5B | $5.1B | EPS beatRevenue miss |
| Q4 FY2025reported Nov 6, 2025 | $3.96 | $3.92 | $5.9B | $5.9B | EPS in lineRevenue in line |
| Q3 FY2025reported Aug 7, 2025 | $3.68 | $3.40 | $5.5B | $5.5B | EPS beatRevenue in line |
| Q2 FY2025reported May 1, 2025 | $3.35 | $3.28 | $5.3B | $5.4B | EPS beatRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Dec 18, 2025| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Thomas E. PolenChairman, Chief Executive Officer and President | $1.4M | $10.0M | $5.7M | $17.1M |
| Christopher J. DelOreficeExecutive Vice President and Chief Financial Officer | $838K | $3.1M | $1.9M | $5.9M |
| Michael C. FeldExecutive Vice President, Chief Revenue Officer and President, Life Sciences Segment | $775K | $1.6M | $1.7M | $4.1M |
| Michael D. GarrisonExecutive Vice President and President, Medical Essentials and BioPharma Systems Segments | $769K | $1.6M | $1.2M | $3.6M |
| Richard E. ByrdExecutive Vice President and President, Interventional Segment | $756K | $1.4M | $1.2M | $3.4M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $3.7B | 24,592,166 | -6.0% | 8.95% |
| Vanguard Capital Management LLC | $2.7B | 17,987,834 | -2.7% | 6.55% |
| Massachusetts Financial Services Co | $2.5B | 8,650,967 | -4.9% | 3.15% |
| State Street Corp | $2.3B | 15,000,064 | +8.5% | 5.46% |
| Vanguard Portfolio Management LLC | $2.3B | 14,974,136 | -2.2% | 5.45% |
| First Eagle Investment Management, LLC | $2.1B | 13,815,335 | +15.8% | 5.03% |
| Invesco Ltd. | $1.3B | 8,898,488 | -12.5% | 3.24% |
| Geode Capital Management, LLC | $1.2B | 8,141,586 | +14.6% | 2.96% |
| Franklin Templeton Inc | $1.1B | 7,011,592 | +30.7% | 2.55% |
| Wellington Management Group LLP | $962.2M | 6,357,986 | -3.9% | 2.31% |
| Greenhaven Associates Inc | $859.8M | 5,681,708 | New | 2.07% |
| Norges Bank | $631.0M | 4,169,523 | New | 1.52% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Open-market insider trades
19 filings shown · newest filing first| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Michael FeldEVP, Chief Revenue Officer | Sold · scheduled | 76 | $183.70 | $14K | Sep 28, 2026filed Sep 29, 2026 | 1d |
| Michael FeldEVP, Chief Revenue Officer | Sold · scheduled | 165 | $188.49 | $31K | Aug 26, 2026filed Aug 27, 2026 | 1d |
| Thomas E. Polen Jr.Chairman, CEO and President | Sold · scheduled | 4,152 | $185.00 | $768K | Aug 13, 2026filed Aug 14, 2026 | 1d |
| Roland GoetteEVP and President, EMEA | Sold | 2,438 | $180.84 | $441K | Aug 11, 2026filed Aug 12, 2026 | 1d |
| Michael FeldEVP, Chief Revenue Officer | Sold · scheduled | 75 | $157.13 | $12K | Jul 27, 2026filed Jul 28, 2026 | 1d |
| Michael FeldEVP, Chief Revenue Officer | Sold · scheduled | 75 | $152.80 | $11K | Jun 26, 2026filed Jun 26, 2026 | 0d |
| Michael David GarrisonEVP & Pres Med.essntl&Biopharm | Sold · scheduled | 1,100 | $145.66 | $160K | Jun 24, 2026filed Jun 25, 2026 | 1d |
| Michael David GarrisonEVP & Pres Med.essntl&Biopharm | Sold · scheduled | 1,100 | $151.48 | $167K | Jun 10, 2026filed Jun 11, 2026 | 1d |
| Thomas E. Polen Jr.Chairman, CEO and President | Sold · scheduled | 2,764 | $146.35 | $405K | Jun 1, 2026filed Jun 3, 2026 | 2d |
| Michael FeldEVP, Chief Revenue Officer | Sold · scheduled | 75 | $147.35 | $11K | May 26, 2026filed May 27, 2026 | 1d |
| Michael FeldEVP, Chief Revenue Officer | Sold · scheduled | 74 | $151.94 | $11K | Apr 27, 2026filed Apr 28, 2026 | 1d |
| Michael FeldEVP, Chief Revenue Officer | Sold · scheduled | 75 | $156.83 | $12K | Mar 26, 2026filed Mar 27, 2026 | 1d |
| Michael FeldEVP, Chief Revenue Officer | Sold · scheduled | 75 | $181.84 | $14K | Feb 26, 2026filed Feb 27, 2026 | 1d |
| Bertram L. ScottDirector | Sold | 953 | $182.61 | $174K | Feb 18, 2026filed Feb 18, 2026 | 0d |
| Michael FeldEVP, CRO & Pres. Life Sciences | Sold · scheduled | 75 | $202.73 | $15K | Jan 26, 2026filed Jan 28, 2026 | 2d |
| Michael David GarrisonEVP & Pres Med.essntl&Biopharm | Sold · scheduled · 2 lines | 1,610 | $207.46 | $334K | Jan 15, 2026filed Jan 16, 2026 | 1d |
| Michael FeldEVP, CRO & Pres. Life Sciences | Sold · scheduled | 74 | $196.08 | $15K | Dec 26, 2025filed Dec 29, 2025 | 1d |
| Michael David GarrisonEVP & Pres Med.essntl&Biopharm | Sold · scheduled | 629 | $196.03 | $123K | Dec 17, 2025filed Dec 17, 2025 | 0d |
| Michael FeldEVP, CRO & Pres. Life Sciences | Sold · scheduled | 75 | $193.36 | $15K | Dec 1, 2025filed Dec 2, 2025 | 1d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Vitor RoqueEVP & Chief Financial Officer | Tax withholding | 190 | Sep 2, 2026 |
| Michael FeldEVP, Chief Revenue Officer | Tax withholding | 1,049 | Aug 20, 2026 |
| Thomas E. Polen Jr.Chairman, CEO and President | Disposed to issuer | 39,126 | Aug 13, 2026 |
| Thomas E. Polen Jr.Chairman, CEO and President | Option exercise | 43,278 | Aug 13, 2026 |
| Carrie L. ByingtonDirector | Stock award | 94 | Aug 6, 2026 |
| Robert Luther HuffinesDirector | Stock award | 189 | Aug 6, 2026 |
| Bilal MuhsinEVP & President Connected Care | Tax withholding | 1,935 | Jul 2, 2026 |
| Bilal MuhsinEVP & President Connected Care | Stock award | 14,342 | Jul 1, 2026 |
| Manish SinhaEVP and Chief People Officer | Other Form 4 entry (see filing) | 2,663 | Nov 26, 2025 |
| Manish SinhaEVP and Chief People Officer | Other Form 4 entry (see filing) | 3,147 | Nov 26, 2024 |
| Manish SinhaEVP and Chief People Officer | Other Form 4 entry (see filing) | 3,408 | Nov 26, 2023 |
| Manish SinhaEVP and Chief People Officer | Other Form 4 entry (see filing) | 3,555 | Nov 26, 2022 |
| Manish SinhaEVP and Chief People Officer | Other Form 4 entry (see filing) | 5,690 | Nov 26, 2021 |
| Manish SinhaEVP and Chief People Officer | Other Form 4 entry (see filing) | 4,441 | Nov 26, 2020 |
| Manish SinhaEVP and Chief People Officer | Other Form 4 entry (see filing) | 4,100 | Nov 26, 2019 |
| Manish SinhaEVP and Chief People Officer | Other Form 4 entry (see filing) | 4,174 | Nov 26, 2018 |
| Thomas E. Polen Jr.Chairman, CEO and President | Disposed to issuer | 17,445 | Jun 1, 2026 |
| Thomas E. Polen Jr.Chairman, CEO and President | Option exercise | 20,209 | Jun 1, 2026 |
| Peter MenziusoEVP and President, BDI | Stock award | 14,258 | Jun 1, 2026 |
| Vitor RoqueEVP & Chief Financial Officer | Stock award | 1,721 | May 7, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Congress trades in BDX
20 disclosures of 133 on record · median 28d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 25, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Alan ArmstrongSelf | Stock | Purchase | $1,001 - $15,000 | +28.7%S&P 500 +19.8% · +8.9 pts vs S&P 500 | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +37.7%After the saleS&P 500 +0.1% · +37.7 pts vs S&P 500 | Jun 2, 2026 | Jul 6, 2026 | 34d |
| Thomas H. Kean, Jr. | Stock | Sale | $1,001 - $15,000 | +36.0%After the saleS&P 500 +2.3% · +33.7 pts vs S&P 500 | May 21, 2026 | Jun 18, 2026 | 28d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +33.2%After the saleS&P 500 +5.4% · +27.8 pts vs S&P 500 | May 1, 2026 | Jun 9, 2026 | 39d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +38.6%S&P 500 +2.8% · +35.8 pts vs S&P 500 | May 15, 2026 | Jun 9, 2026 | 25d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +35.1%S&P 500 +1.3% · +33.8 pts vs S&P 500 | May 27, 2026 | Jun 9, 2026 | 13d |
| Ro Khanna | Stock | Sale | $15,001 - $50,000 | +28.0%After the saleS&P 500 +10.8% · +17.2 pts vs S&P 500 | Apr 13, 2026 | May 11, 2026 | 28d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +30.7%After the saleS&P 500 +6.4% · +24.3 pts vs S&P 500 | Apr 24, 2026 | May 11, 2026 | 17d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +27.3%S&P 500 +15.6% · +11.7 pts vs S&P 500 | Mar 23, 2026 | Apr 7, 2026 | 15d |
| Kevin HernJoint | Stock | Sale | $15,001 - $50,000 | +23.1%After the saleS&P 500 +13.2% · +9.8 pts vs S&P 500 | Mar 17, 2026 | Apr 3, 2026 | 17d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -1.4%S&P 500 +10.2% · -11.6 pts vs S&P 500 | Jan 23, 2026 | Feb 6, 2026 | 14d |
| Ro Khanna | Stock | Purchase | $15,001 - $50,000 | -1.1%S&P 500 +9.5% · -10.5 pts vs S&P 500 | Jan 29, 2026 | Feb 6, 2026 | 8d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +12.2%After the saleS&P 500 +11.2% · +1.0 pts vs S&P 500 | Nov 3, 2025 | Dec 8, 2025 | 35d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +9.5%After the saleS&P 500 +11.5% · -2.0 pts vs S&P 500 | Nov 10, 2025 | Dec 8, 2025 | 28d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +8.1%S&P 500 +14.5% · -6.4 pts vs S&P 500 | Sep 29, 2025 | Oct 3, 2025 | 4d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +11.2%S&P 500 +20.4% · -9.2 pts vs S&P 500 | Aug 4, 2025 | Sep 9, 2025 | 36d |
| Lisa C. McClainSpouse | Stock | Purchase | $1,001 - $15,000 | +17.1%S&P 500 +27.2% · -10.1 pts vs S&P 500 | Jun 17, 2025 | Aug 13, 2025 | 57d |
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +15.9%After the saleS&P 500 +24.9% · -8.9 pts vs S&P 500 | Jun 24, 2025 | Aug 13, 2025 | 50d |
| Thomas H. Kean, Jr. | Stock | Purchase | $1,001 - $15,000 | +13.4%S&P 500 +29.5% · -16.1 pts vs S&P 500 | May 13, 2025 | Jun 17, 2025 | 35d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +12.4%S&P 500 +27.8% · -15.4 pts vs S&P 500 | May 19, 2025 | Jun 10, 2025 | 22d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in BDX, filterable by party, chamber, type and account.
Members of Congress reporting a position
6 members · estimate, as of Oct 23, 20266 members report a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Tom Cole | Republican · House | $50,001 - $100,000 | 9.6% |
| Debbie Dingell | Democrat · House | $15,001 - $50,000 | 0.4% |
| Jacky Rosen | Democrat · Senate | $15,001 - $50,000 | 0.5% |
| Thomas H. Kean, Jr. | Republican · House | $15,001 - $50,000 | 0.5% |
| Gilbert Ray Cisneros, Jr. | Democrat · House | $1,001 - $15,000 | <0.1% |
| Lucy McBath | Democrat · House | $1,001 - $15,000 | 0.1% |
Estimate, as of Oct 23, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Are insiders buying or selling BDX?
Across the 19 most recent open-market filings shown here, 0 were purchases and 19 were sales. 17 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded BDX?
Alan Armstrong, Ro Khanna, Thomas H. Kean, Jr., Kevin Hern and Lisa C. McClain disclosed BDX transactions in the filings shown here.
Which members of Congress hold BDX?
6 members of Congress report a position in BDX in the estimate we hold as of Oct 23, 2026. The largest estimated position belongs to Tom Cole; the next largest, in the $15,001 - $50,000 band, include Debbie Dingell and Jacky Rosen. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is BDX in the S&P 500 or the Nasdaq 100?
Becton, Dickinson and Company is a current member of the S&P 500, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.
How quickly are BDX trades disclosed?
Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.
